BridgeBio Pharma, Inc.

Company Overview

Business Model: BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with genetic diseases. The company generates revenue through net product sales of its approved therapies and through licensing and royalty agreements with pharmaceutical partners for international commercialization. Its strategy involves advancing multiple programs from discovery through regulatory approval and commercialization, with a focus on efficient development.

Market Position: BridgeBio Pharma, Inc. has successfully brought three products to FDA approval, treating over 8,500 patients. Its lead commercial product, Attruby (acoramidis), is the first and only FDA-approved product with a label specifying near-complete stabilization of transthyretin (TTR) for transthyretin amyloid cardiomyopathy (ATTR-CM). The company estimates a >25% share of new-to-brand prescriptions (NBRx) for Attruby in the U.S. and >50% for Beyonttra (acoramidis) in Germany within its first year of launch. The total market for ATTR therapeutic interventions is estimated to exceed $20.0 billion. BridgeBio Pharma, Inc. also has a robust late-stage pipeline with several programs that have met primary and key secondary endpoints in Phase 3 studies, positioning it to potentially introduce first-in-class therapies for conditions like Autosomal Dominant Hypocalcemia Type 1 (ADH1) and Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9).

Recent Strategic Developments:

• Attruby/Beyonttra Approvals & Commercialization: FDA approval for Attruby in November 2024, followed by European Commission, UK, Switzerland, and Japanese approvals for Beyonttra in 2025.
• Strategic Licensing Agreements: Exclusive license agreements with Bayer for Beyonttra in Europe (March 2024) and Alexion Pharma International Operations Limited Company for Beyonttra in Japan (September 2019). Exclusive license agreement with Kyowa Kirin Co., Ltd for infigratinib in Japan (February 2024).
• Successful Phase 3 Readouts: Positive topline results for infigratinib in achondroplasia (February 2026), encaleret for ADH1 (October 2025), and BBP-418 for LGMD2I/R9 (October 2025), indicating strong potential for future regulatory submissions and commercialization.
• Capital Raising: Issued $575.0 million in 1.75% Convertible Senior Notes due 2031 (February 2025) and $632.5 million in 0.75% Convertible Senior Notes due 2033 (January 2026). Completed a $300.0 million royalty interest sale on acoramidis in Europe (June 2025) and received $500.0 million from a funding agreement upon FDA approval of Attruby (December 2024).
• Portfolio Management: Accelerated approval for Truseltiq (infigratinib) was withdrawn by the FDA in May 2023, leading to its commercial discontinuation.

Geographic Footprint: BridgeBio Pharma, Inc. has a global presence with commercial operations and development programs spanning the U.S., Europe, and Asia-Pacific regions.

• Primary Operational Regions: U.S. (Palo Alto, CA; San Francisco, CA; Raleigh, NC) and Canada (Montreal, Québec) for R&D and corporate functions.
• Key Markets: U.S. is the primary market for Attruby. Europe (EU member states, UK, Switzerland) and Japan are key international markets for Beyonttra through partnerships with Bayer and Alexion Pharma International Operations Limited Company, respectively. Japan is also a key market for infigratinib through a partnership with Kyowa Kirin Co., Ltd.
• Geographic Revenue Distribution (2025): U.S. 72.2%, Europe, Middle East, and Africa (EMEA) 25.3%, Asia-Pacific (APAC) 2.5%.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 95.8%
• Operating Margin: -104.3%
• Net Margin: -146.0%

Investment in Growth (2025):

• R&D Expenditure: $452.0 million (90.0% of revenue)
• Strategic Investments: Equity method investments totaled $79.97 million as of December 31, 2025.

Business Segment Analysis

Commercial Products

Attruby (acoramidis)

Financial Performance (2025):

• Net Product Revenue: $362.4 million
• Key Growth Drivers: FDA approval in November 2024, strong uptake with 7,804 unique patient prescriptions and 1,856 prescribing healthcare professionals in the U.S. by February 2026. Estimated >25% share of new-to-brand prescriptions (NBRx).
• U.S. list price: $18,759.12 for a 28-day supply (through December 2025), increased to $19,790.00 (January 2026).

Product Portfolio:

• Attruby (acoramidis) is approved for transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. It is the first and only approved product with a label specifying near-complete stabilization of TTR.

Market Dynamics:

• Estimated 240,000 ATTR-CM patients in the U.S., part of a global patient population of around 500,000. The total market for ATTR therapeutic interventions could exceed $20.0 billion.
• Patient access programs include Commercial Co-Pay, Patient Assistance Program (PAP), and a free 28-day trial. Medicare patients' out-of-pocket costs are capped at $2,000 annually, effective January 1, 2025, under the Inflation Reduction Act.

Beyonttra (acoramidis)

Financial Performance (2025):

• License and Services Revenue: $105.0 million (following approvals in Europe and Japan)
• Royalty Revenue: $11.4 million (primarily from Europe and Japan)
• Key Growth Drivers: European Commission approval in February 2025, UK and Switzerland approvals in 2025, and Japanese approval in March 2025. Strong initial market penetration in Germany with an estimated >50% NBRx share.

Product Portfolio:

• Beyonttra (acoramidis) is approved for ATTR-CM in Europe and Japan.

Market Dynamics:

• Commercial rights licensed to Bayer in Europe and Alexion Pharma International Operations Limited Company in Japan, leveraging established regional commercial infrastructures.

Nulibry (fosdenopterin)

Financial Performance (2025):

• BridgeBio Pharma, Inc. did not generate significant royalty revenue from Nulibry in 2025.
• Global rights were acquired by Sentynl Therapeutics, Inc. in March 2022.

Product Portfolio:

• Nulibry (fosdenopterin) was approved by the FDA in February 2021 for Molybdenum Cofactor Deficiency (MoCD) Type A.

Truseltiq (infigratinib)

Financial Performance:

• Accelerated approval withdrawn by FDA in May 2023; no longer commercially available.

Development Pipeline (R&D Expenditure by Program)

Infigratinib for Achondroplasia

Financial Performance (2025):

• R&D Expenditure: $122.7 million (+33.5% YoY)
• Key Growth Drivers: Positive topline results from PROPEL 3 global pivotal study (Phase 3) met primary and key secondary endpoints (AHV +2.10 cm/year vs. placebo, height Z-score increase +0.41 SD). Well-tolerated safety profile.
• Plans: Submit NDA to FDA and MAA to EMA in second half of 2026.
• Market Opportunity: Potentially over $5.0 billion total global market, with prevalence >55,000 in U.S. and Europe.
• Designations: FDA Breakthrough Therapy, Rare Pediatric Disease, Fast Track, Orphan Drug.

Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Financial Performance (2025):

• R&D Expenditure: $60.0 million (+22.1% YoY)
• Key Growth Drivers: CALIBRATE trial (Phase 3) met all primary and key secondary endpoints (76% achieved serum/urine calcium targets vs. 4% on conventional therapy; 91% achieved intact PTH levels vs. 7%). Well-tolerated safety profile.
• Plans: Submit NDA to FDA in first half of 2026, followed by MAA to EMA. Initiate registrational Phase 2/3 study in pediatric ADH1 in Q1 2026.
• Market Opportunity: 25,000 carriers of ADH1-causative variants in EU and US. Could be the first targeted therapy for ADH1.
• Designations: FDA Orphan Drug, Fast Track; European Commission and Japan Ministry of Health, Labor and Welfare Orphan Designation.

BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

Financial Performance (2025):

• R&D Expenditure: $56.0 million (+39.2% YoY)
• Key Growth Drivers: FORTIFY study (Phase 3) interim analysis met all primary and key secondary endpoints (1.8-fold increase in glycosylated αDG, 82% mean reduction in serum CK, statistically significant improvements in ambulatory and pulmonary function, 2.6 point benefit on NSAD). Well-tolerated safety profile.
• Plans: Submit NDA to FDA in first half of 2026. May be eligible for a Priority Review Voucher.
• Market Opportunity: Estimated approximately 7,000 individuals across the U.S. and Europe. Could be the first disease-modifying therapy for LGMD2I/R9.
• Designations: FDA Orphan Drug, Fast Track, Rare Pediatric Disease; EMA Orphan Drug.

Encaleret for Chronic Hypoparathyroidism (CHP)

Financial Performance (2025):

• R&D expenditure is included within the broader Encaleret program.
• Key Growth Drivers: Phase 2 proof-of-concept study completed September 2025, showing PTH-independent normalization of blood and urine calcium in 80% of participants within 5 days vs. 0% on conventional therapy.
• Plans: Initiate registrational Phase 3 study in adults with CHP in summer of 2026.
• Market Opportunity: Estimated 200,000 patients in US and Europe.

Other Development Programs

Financial Performance (2025):

• R&D Expenditure: $22.7 million (-68.3% YoY)
• Includes programs like infigratinib for Hypochondroplasia (ACCEL 2/3 Phase 2 enrollment completed, results expected H2 2026) and BBP-812 for Canavan disease (Phase 1/2 study ongoing).

Other Research Programs

Financial Performance (2025):

• R&D Expenditure: $73.8 million (-16.9% YoY)
• Includes early-stage programs such as Evanesco (next-generation depleter for ATTR-CM, monoclonal antibody, plans to advance into clinic in 2027–2028).
• Strategic Investments: Held a 27.5% ownership interest in GondolaBio, LLC (Phase 2a program PORT-77 for erythropoietic protoporphyria (EPP)). Held an 18.2% ownership interest in BridgeBio Oncology Therapeutics, Inc. (BBOT), which listed on Nasdaq in August 2025.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases:
  • $48.3 million for 1,405,411 shares in 2025 (related to 2031 Notes issuance).
  • $50.0 million for 759,993 shares in 2021 (related to 2029 Notes issuance).
  • $75.0 million for 2,414,681 shares in 2020 (related to 2027 Notes issuance).
  • Subsequent Event (January 21, 2026): $82.5 million for 1,081,825 shares (related to 2033 Notes issuance).
• Dividend Payments: Not disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $570.1 million
• Total Debt: $1.9 billion (comprising 2031, 2029, and 2027 Notes)
• Net Cash Position: $(1.3) billion (Net Debt)
• Deferred Royalty Obligations: $855.0 million
• Accumulated Deficit: $3.8 billion

Credit Rating: Not disclosed.

Debt Maturity Profile (Principal amounts in thousands as of December 31, 2025):

Cash Flow Generation (2025):

• Operating Cash Flow: $(445.9) million (Net cash used in operating activities)
• Free Cash Flow: Not explicitly stated.

Operational Excellence

Production & Service Model: BridgeBio Pharma, Inc. operates a fully outsourced manufacturing and supply chain model. It relies entirely on third-party contract manufacturing organizations (CMOs) for all raw materials, drug substance, drug product, and packaging for its commercial products (Attruby and Beyonttra) and clinical trial materials.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturing Organizations (CMOs): BridgeBio Pharma, Inc. is dependent on a small number of CMOs for active pharmaceutical ingredients and formulated drugs. For certain clinical product candidates, the company relies on a single-source manufacturer.
• Third-Party Logistics Providers: Utilizes a limited network of specialty pharmacies, specialty distributors, and third-party logistics providers for U.S. distribution of Attruby.

Facility Network:

• Manufacturing: Outsourced to third-party CMOs; no owned manufacturing facilities.
• Research & Development:
  • Palo Alto, CA: 24,428 sq ft office and laboratory facility (leased, initial term ends 2026).
  • Raleigh, NC: 21,263 sq ft office and laboratory facility (leased, initial term ends 2026).
  • Montreal, Québec: 20,039 sq ft laboratory facility (leased, initial term ends 2032).
• Distribution: Outsourced to third-party logistics providers.
• Corporate Offices: San Francisco, CA: 52,604 sq ft office space (leased, initial term ends 2027).

Operational Metrics:

• Attruby U.S. Patient Prescriptions: 7,804 unique patients as of February 20, 2026.
• Attruby U.S. Prescribing Healthcare Professionals: 1,856 as of February 20, 2026.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales (U.S.): For Attruby, BridgeBio Pharma, Inc. utilizes a limited network of specialty pharmacies, specialty distributors, and third-party logistics providers.
• Channel Partners (International):
  • Bayer: Exclusive license for Beyonttra in Europe (EU member states, UK, Switzerland, Turkey).
  • Alexion Pharma International Operations Limited Company: Exclusive license for Beyonttra in Japan.
  • Kyowa Kirin Co., Ltd: Exclusive license for infigratinib in Japan.
• Digital Platforms: Not explicitly detailed.

Customer Portfolio: Customer Concentration (10% or greater of consolidated total gross revenues in 2025):

• Bayer: 14.4%
• Customer A: 18.5%
• Customer B: 19.8%
• Customer C: 14.5%
• Customer D: 14.5%
• Customer E: 11.1%

Customer Concentration (10% or greater of consolidated gross accounts receivable in 2025):

• Five customers accounted for 27.0%, 20.3%, 19.1%, 15.0%, and 14.9% respectively.

Geographic Revenue Distribution (as % of total revenues, net):

• U.S.: 72.2% (2025), 6.0% (2024)
• Europe, Middle East, and Africa (EMEA): 25.3% (2025), 59.5% (2024)
• Asia-Pacific (APAC): 2.5% (2025), 34.5% (2024)

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: BridgeBio Pharma, Inc. operates in the biopharmaceutical industry, specifically targeting genetic diseases, which often represent orphan or ultra-orphan indications. These markets are characterized by high unmet medical needs, significant R&D investment, complex regulatory pathways, and often high pricing for approved therapies due to small patient populations and development costs. The ATTR market is estimated to exceed $20.0 billion, with diagnosed ATTR-CM patients in the U.S. growing from fewer than 5,000 in 2019 to over 50,000 in 2025. Achondroplasia has a global market opportunity potentially over $5.0 billion.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Attruby/Beyonttra (acoramidis) for ATTR-CM:
  • Pfizer, Inc.: Vyndaqel / Vyndamax (tafamidis meglumine / tafamidis) - approved in U.S., EU, Japan.
  • Alnylam Pharmaceuticals, Inc.: vutrisiran - approved in 2025 for ATTR-CM.
• Infigratinib for Achondroplasia:
  • BioMarin Pharmaceutical Inc.: Voxzogo® (vosoritide) - approved in U.S., EU, Japan, Brazil, Australia.
  • Ascendis Pharma A/S: TransCon CNP (in development).
  • Tyra Biosciences, Inc.: TYRA-300 (in development).
  • Ribomic: RBM-007 (in development).
• BBP-418 for LGMD2I/R9: No currently approved therapies.
• Encaleret for ADH1: No currently approved disease-modifying therapies.

Emerging Competitive Threats:

• New entrants and disruptive technologies in genetic disease therapies, including gene therapies and other novel modalities.

Competitive Response Strategy: BridgeBio Pharma, Inc.'s strategy involves developing differentiated therapies with strong clinical outcomes, securing expedited regulatory designations, and leveraging strategic partnerships for broader market access. For Attruby/Beyonttra, the company highlights its near-complete TTR stabilization as a key differentiator. For pipeline assets, the focus is on being first-in-class for indications with no approved therapies.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Competition: Intense competition from established players and new entrants in genetic disease markets.
• Technology Disruption: Risk of new technologies or therapies rendering current or pipeline products obsolete.
• Customer Concentration: Significant revenue concentration from a few key customers and licensing partners (e.g., Bayer, Alexion Pharma International Operations Limited Company, Kyowa Kirin Co., Ltd).

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Heavy reliance on third-party contract manufacturing organizations (CMOs) and a small number of manufacturers for raw materials, drug substance, and drug product.
• Single-Source Reliance: Dependence on single-source manufacturers for certain clinical product candidates.
• Capacity Constraints: Potential for production bottlenecks or supply disruptions from third-party manufacturers.

Financial & Regulatory Risks

Market & Financial Risks:

• Demand Volatility: Demand for products can be influenced by diagnostic rates, patient access, and competitive landscape.
• Foreign Exchange: Exposure to currency fluctuations due to international sales and licensing agreements.
• Credit & Liquidity: Continued net losses and accumulated deficit ($3.8 billion as of December 31, 2025) necessitate ongoing capital raising.
• Inflationary Factors: While not material in recent periods, inflation could impact operational costs.

Regulatory & Compliance Risks:

• Industry Regulation: Subject to extensive and evolving regulations by the FDA, European Commission, and other international bodies.
• Pricing Pressure: Impact of government initiatives like the Inflation Reduction Act (IRA) in the U.S. (e.g., Medicare Part D out-of-pocket cap, drug price negotiation for certain drugs) and international pricing benchmarks (e.g., CMS's proposed GUARD and GLOBE Models). Orphan drugs are exempt from Medicare drug price negotiation for the 2028 initial price applicability year.
• Data Privacy: Compliance with regulations such as EU GDPR, UK GDPR, and U.S. state-specific laws (e.g., Washington’s My Health My Data Act).
• Export Controls: Potential impact of trade restrictions and sanctions on global operations.

Geopolitical & External Risks

Geopolitical Exposure:

• Government Shutdowns: U.S. government shutdowns can impact regulatory review timelines and operations.
• Trade Relations: Impact of trade tensions and policy changes (e.g., U.S. Supreme Court invalidating reciprocal tariffs in February 2026).

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Genetic Diseases: Primary focus on discovering and developing medicines for a wide range of genetic diseases.
• Transthyretin Stabilization: Expertise in small molecule TTR stabilizers, exemplified by acoramidis.
• FGFR Inhibition: Development of selective FGFR1-3 tyrosine kinase inhibitors like infigratinib.
• Calcium Sensing Receptor Modulation: Development of negative allosteric modulators of CaSR, such as encaleret.
• Glycosylation Pathways: Research into therapies for glycosylation defects, such as BBP-418 for LGMD2I/R9. Innovation Pipeline:
• Evanesco (Depleter): Next-generation monoclonal antibody program for ATTR-CM, planned to advance into clinic in 2027–2028.
• GondolaBio, LLC: Developing PORT-77 (small-molecule ABCG2 inhibitor) in Phase 2a for erythropoietic protoporphyria (EPP), with plans to initiate Phase 2b/3 in 2026.
• BridgeBio Oncology Therapeutics, Inc. (BBOT): Focus on oncology therapeutics, with BridgeBio Pharma, Inc. holding an 18.2% ownership interest.

Intellectual Property Portfolio:

• Patent Strategy: Over 200 issued patents and over 300 patent applications globally. Actively pursues patent term extensions (PTE) for key assets.
• Infigratinib: Licensed from Novartis (U.S. patents expire 2028-2029, PTE application filed to extend to 2033), and Inserm Transfert ESA/Assistance Publique-Hôpitaux de Paris (expire 2032). QED owns pending applications (if issued, expire 2041-2044).
• Acoramidis: Licensed from Stanford (U.S. patents expire 2031 or 2033, PTE applications filed). Eidos Therapeutics, Inc. owns patents (issued expire 2038 or 2039; pending if issued expire 2038-2044).
• Encaleret: Licensed from Japan Tobacco Company (expired 2024-2025). Calcilytix Therapeutics, Inc. owns/co-owns patents (if issued, expire 2041-2044, not including PTE).
• BBP-418: Licensed from Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health (issued U.S. patents expire 2037 or 2040, not including PTE; pending if issued expire 2037-2041, not including PTE). ML Bio Solutions, Inc. owns pending applications (if issued, expire 2044).

Technology Partnerships:

• Novartis: Licensing agreement for infigratinib.
• Inserm Transfert ESA and Assistance Publique-Hôpitaux de Paris: Licensing agreement for infigratinib.
• Stanford University: Licensing agreement for acoramidis.
• Japan Tobacco Company: Licensing agreement for encaleret.
• Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health: Licensing agreement for BBP-418.

Leadership & Governance

Executive Leadership Team

Specific C-suite executive names, tenures, and prior experiences are not explicitly detailed in the provided filing excerpt.

Leadership Continuity: Not explicitly detailed.

Board Composition: The Board of Directors, through its Audit Committee, oversees enterprise risks, including cybersecurity. The Data Privacy and Security Committee reports to the Audit Committee. Directors Dr. Hannah A. Valantine, Ms. Andrea J. Ellis, and Dr. Frank McCormick adopted Rule 10b5-1 trading plans in late 2025.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 834 full-time and 5 part-time employees.
• Skill Mix:
  • R&D Programs: 405 employees
  • Commercialization Efforts: 281 employees
  • Strategic Business Development, Finance, Executive Leadership, and General and Administrative Services: 153 employees

Talent Management: Acquisition & Retention:

• Employee Value Proposition: Utilizes stock-based compensation as a significant component of employee remuneration.
• Stock-Based Compensation (2025): Total stock-based compensation was $133.0 million, with $49.3 million allocated to R&D and $84.7 million to selling, general and administrative expenses.
• Stock Options: 11.5 million options outstanding (weighted-average exercise price $25.76).
• Restricted Stock Units (RSUs): 8.9 million time-based unvested shares, 194.7 thousand performance-based unvested shares, and 232.1 thousand market-based outstanding shares.
• Employee Stock Purchase Plan (ESPP): Employees purchased 261,422 shares for $6.4 million in 2025.

Diversity & Development: Not explicitly detailed in the provided filing.

Culture & Engagement: No work stoppages have occurred, and no employees are represented by a labor organization.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• FDA Regulation: Drugs regulated under the Federal Food, Drug and Cosmetic Act (FDCA) and biologics under FDCA and Public Health Service Act (PHSA). Requires Investigational New Drug (IND) applications, clinical trials (Phase 1, 2, 3), and New Drug Applications (NDAs)/Biologics License Applications (BLAs).
• Expedited Programs: Utilizes FDA designations such as Breakthrough Therapy, Rare Pediatric Disease, Fast Track, Orphan Drug, Accelerated Approval, and Regenerative Medicine Advanced Therapy (RMAT). Orphan Drug Designation grants 7 years of exclusivity, now codified to apply only to the specific approved use/indication. Rare Pediatric Disease Designation may lead to a Priority Review Voucher (PRV), reauthorized through September 30, 2029.
• Post-marketing Requirements: Compliance with cGMP, PDMA, and DSCSA.
• EU Regulation: Subject to EU Clinical Trials Regulation (EU) No 536/2014 and EU marketing authorization procedures (centralized procedure). Grants 8 years data exclusivity + 2 years market exclusivity (up to 11 years) for new chemical entities, and 10 years market exclusivity for orphan designations (reducible to 6 years).
• Brexit Impact: UK not generally subject to EU laws since January 1, 2021, with the Windsor Framework (January 1, 2025) reintegrating Northern Ireland under the MHRA.
• Companion Diagnostics: Regulated as medical devices; FDA intends to reclassify most in vitro diagnostics as Class II devices.

Trade & Export Controls:

• Export Restrictions: Subject to country-specific limitations and licensing requirements.
• Sanctions Compliance: Compliance with sanctioned entity restrictions and monitoring.

Legal Proceedings:

• As of the date of the Annual Report on Form 10-K, BridgeBio Pharma, Inc. was not party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile (2025):

• Effective Tax Rate: (0.1)%
• Federal Net Operating Loss (NOL) Carryforwards: Approximately $1.7 billion (as of December 31, 2025). Federal NOLs after 2018 carry over indefinitely, subject to an 80% taxable income limitation.
• State NOL Carryforwards: $462.2 million (as of December 31, 2025), generally begin to expire in 2036.
• Foreign NOL Carryforwards: $543.0 million (as of December 31, 2025), begin to expire in 2030.
• Federal R&D and Orphan Drug Credit Carryforwards: Approximately $141.3 million (as of December 31, 2025), expire beginning in 2038.
• State R&D Tax Credit Carryforwards: $37.4 million (as of December 31, 2025).
• Valuation Allowance: Increased by $240.7 million in 2025.
• Unrecognized Tax Benefits: $44.0 million (as of December 31, 2025).

Tax Reform Impact:

• The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, permanently reinstated the immediate deduction of domestic research and experimental expenditures.